Notice: This company has been marked as potentially delisted and may not be actively trading. Vallon Pharmaceuticals (VLON) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends VLON vs. RLYB, QTTB, XLO, SCYX, ATNM, CLNN, BRNS, LTRN, CALC, and VYNEShould you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include Rallybio (RLYB), Q32 Bio (QTTB), Xilio Therapeutics (XLO), SCYNEXIS (SCYX), Actinium Pharmaceuticals (ATNM), Clene (CLNN), Barinthus Biotherapeutics (BRNS), Lantern Pharma (LTRN), CalciMedica (CALC), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical preparations" industry. Vallon Pharmaceuticals vs. Rallybio Q32 Bio Xilio Therapeutics SCYNEXIS Actinium Pharmaceuticals Clene Barinthus Biotherapeutics Lantern Pharma CalciMedica VYNE Therapeutics Vallon Pharmaceuticals (NASDAQ:VLON) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations. Is VLON or RLYB more profitable? Rallybio's return on equity of -77.39% beat Vallon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vallon PharmaceuticalsN/A -230.48% -124.89% Rallybio N/A -77.39%-69.33% Which has stronger valuation & earnings, VLON or RLYB? Vallon Pharmaceuticals has higher earnings, but lower revenue than Rallybio. Vallon Pharmaceuticals is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVallon Pharmaceuticals$100K99.77-$7.02M-$0.78-0.95Rallybio$598K65.91-$74.56M-$1.60-0.59 Do analysts prefer VLON or RLYB? Rallybio has a consensus price target of $9.75, indicating a potential upside of 926.32%. Given Rallybio's stronger consensus rating and higher possible upside, analysts plainly believe Rallybio is more favorable than Vallon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vallon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community prefer VLON or RLYB? Rallybio received 40 more outperform votes than Vallon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Vallon Pharmaceuticals an outperform vote while only 77.36% of users gave Rallybio an outperform vote. CompanyUnderperformOutperformVallon PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesRallybioOutperform Votes4177.36% Underperform Votes1222.64% Do insiders & institutionals have more ownership in VLON or RLYB? 8.7% of Vallon Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 37.3% of Vallon Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to VLON or RLYB? In the previous week, Vallon Pharmaceuticals' average media sentiment score of 0.00 equaled Rallybio'saverage media sentiment score. Company Overall Sentiment Vallon Pharmaceuticals Neutral Rallybio Neutral Which has more volatility & risk, VLON or RLYB? Vallon Pharmaceuticals has a beta of -1.14, indicating that its stock price is 214% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.55, indicating that its stock price is 255% less volatile than the S&P 500. SummaryRallybio beats Vallon Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Vallon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VLON vs. The Competition Export to ExcelMetricVallon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.98M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.9510.5589.7417.16Price / Sales99.77196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book4.115.094.784.78Net Income-$7.02M$151.83M$120.31M$225.60M Vallon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VLONVallon PharmaceuticalsN/A$0.74-3.9%N/A+99.4%$9.98M$100,000.00-0.953RLYBRallybio2.6948 of 5 stars$1.03-4.6%$9.75+846.6%-63.6%$42.74MN/A-0.6740QTTBQ32 Bio2.8291 of 5 stars$3.50-5.4%$29.86+753.1%N/A$42.63M$-6,651,000.00-0.2439High Trading VolumeXLOXilio Therapeutics2.7965 of 5 stars$0.96-1.1%$4.00+317.6%+140.9%$42.11MN/A-0.5473News CoverageGap UpSCYXSCYNEXIS0.8217 of 5 stars$1.08-5.3%N/A-46.5%$40.99M$8.57M-1.4660Gap DownATNMActinium Pharmaceuticals1.2441 of 5 stars$1.27+3.3%$7.40+482.7%N/A$39.62M$81,000.00-0.8849CLNNClene3.73 of 5 stars$4.70-5.1%$55.25+1,075.5%-30.2%$39.29M$650,000.00-0.94100Analyst ForecastNews CoverageBRNSBarinthus Biotherapeutics1.5315 of 5 stars$0.97+6.8%$5.83+498.8%-66.8%$39.19M$800,000.00-0.61107Gap UpLTRNLantern PharmaN/A$3.56+3.5%N/A-24.0%$38.40MN/A-1.9420Gap DownCALCCalciMedica2.9477 of 5 stars$2.81+2.9%$19.33+588.0%-7.1%$37.88MN/A-2.5330Positive NewsVYNEVYNE Therapeutics2.6593 of 5 stars$2.56flat$6.88+168.6%-1.6%$37.76M$493,000.00-2.9830News Coverage Related Companies and Tools Related Companies RLYB Alternatives QTTB Alternatives XLO Alternatives SCYX Alternatives ATNM Alternatives CLNN Alternatives BRNS Alternatives LTRN Alternatives CALC Alternatives VYNE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VLON) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
